Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. is a leading commercial-stage medical device company based in Silicon Valley, focused on transforming the lives of individuals suffering from epilepsy. Founded with the mission to design, develop, manufacture, and market implantable devices for neurological disorders, NeuroPace has made significant strides in the field of responsive neurostimulation.
At the core of NeuroPace's innovation is the RNS® System. This award-winning technology, akin to a pacemaker for the heart, is the world's first and only medical device capable of monitoring and responding to brain activity in real-time. The RNS® System is specifically designed to treat epilepsy, a neurological disorder that affects approximately 1% of the global population, by reducing or eliminating debilitating seizures. The system is primarily used in hospital facilities, particularly Level 4 Comprehensive Epilepsy Centers (CECs).
Beyond epilepsy, the promise of responsive neurostimulation extends to several other disabling medical conditions, potentially improving the quality of life for millions worldwide. NeuroPace is recognized for its patient-centric approach and continuous advancements in the field of neurological treatments.
Recent achievements include the RNS® System being featured in over 50 scientific presentations and posters, underscoring its impact and the ongoing research dedicated to improving its efficacy. The company also maintains significant partnerships and collaborations to further its mission and ensure the RNS® System remains at the forefront of medical innovation.
Financially, NeuroPace derives nearly all its revenue from the sales of the RNS® System, highlighting the product's centrality to the company’s business model. With a strong focus on patient outcomes and continuous technological advancement, NeuroPace is well-positioned to lead in the field of neurological disorder treatments.
NeuroPace (NASDAQ: NPCE) announced its participation in the 2024 American Epilepsy Society Annual Meeting (AES 2024) at the Los Angeles Convention Center from December 6-10, 2024. The company's RNS System will be featured in over 70 scientific presentations and posters.
At booth #2119, NeuroPace will showcase their responsive neuromodulation technology, highlighting 82% seizure reduction at three years and improved quality of life without chronic side effects common in other neuromodulation therapies. The company is hosting demonstrations, panels, and networking events, including a Fellows Networking Reception and a Product Theater presentation on 'New Frontiers in Responsive Neuromodulation.'
NeuroPace announced completion of enrollment and implant procedures in its feasibility IDE study of the RNS System for treating Lennox-Gastaut Syndrome (LGS), a severe childhood-onset epilepsy. The study, funded by a $9.3 million NIH grant, enrolled 20 patients aged 12 and older across six sites to evaluate the safety and effectiveness of brain-responsive stimulation for LGS treatment.
The study includes a one-year open label period followed by an 18-month long-term follow-up. LGS affects patients severely, with 85% continuing to have seizures into adulthood, 98% suffering from intellectual disability, and affected individuals being 12 times more likely to die prematurely than their peers.
NeuroPace reported a 28% year-over-year revenue increase to $21.1 million in Q3 2024, driven by higher RNS System sales. The company raised its full-year 2024 revenue guidance to $78-80 million. Gross margin was strong at 73.2%. Cash burn decreased to $1.8 million, with an increase in cash and short-term investments to $56.8 million. Operating expenses rose to $19.7 million, primarily due to increased R&D and SG&A costs. Net loss narrowed to $5.5 million from $7.3 million in Q3 2023. Management highlighted positive three-year data from a Post-Approval Study and announced an investor day in Q1 2025.
NeuroPace has submitted three-year safety and effectiveness data from its Post-Approval Study (PAS) of the RNS System to the FDA. The study, involving over 300 patients from more than 30 Level 4 Comprehensive Epilepsy Centers in the US, is the largest prospective trial in neuromodulation for drug-resistant focal epilepsy. The RNS System is the only neuromodulation device that provides stimulation and monitors patient response over time. The study will continue to a five-year follow-up endpoint as part of the system's initial FDA approval.
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, has announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors can access a live and archived webcast of the event at the provided link. Those interested in participating via telephone can dial +1-877-407-3982 and reference Conference ID 13749123. The webcast will be archived on the company's investor relations website for at least 90 days after the event.
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has appointed Amy Treadwell as its new Vice President of Human Resources. CEO Joel Becker emphasized the importance of this appointment in supporting the company's growth and capitalizing on commercial, operating, and technological opportunities. Ms. Treadwell brings significant experience from healthcare and technology roles, having previously served as VP of People at CyCognito and held HR leadership positions at Carbon Health, Fitbit, and eBay.
This appointment, along with recent additions of Brett Wingeier as VP of Research and Development and Katie Keller as VP of Marketing, aims to strengthen NeuroPace's management team and enhance its strategy to increase access, adoption, and utilization of RNS therapy. Ms. Treadwell holds a Juris Doctor degree from Santa Clara University School of Law and a Bachelor's degree in International Relations from the University of Southern California.
NeuroPace (NPCE) has strengthened its management team with two key appointments. Brett Wingeier joins as the new Vice President of Research and Development, bringing over 20 years of experience in neurotech and biomedical engineering, including a decade as a key contributor to the development of NeuroPace's RNS System. Katie Keller has been appointed as the new Vice President of Marketing, bringing significant experience in medical device marketing, particularly from her role leading the global commercial marketing for Boston Scientific's Neuromodulation Deep Brain Stimulation franchise.
These appointments aim to enhance NeuroPace's market development programs, drive broader adoption of RNS therapy, and advance the company's strategy to expand the capabilities of the RNS System. Both executives express excitement about joining NeuroPace and contributing to its mission of transforming the lives of people living with epilepsy.
NeuroPace (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has announced its participation in two upcoming healthcare investor conferences in September. The company will:
- Host one-on-one meetings with investors at the Lake Street Big8 Best Ideas Growth Conference on September 12th in New York
- Present at the Cantor Global Healthcare Conference from September 17th-19th in New York, featuring a fireside chat with CEO Joel Becker and CFO Rebecca Kuhn on September 18th at 11:30am ET
The fireside chat will be available via live webcast and a replay will be accessible on NeuroPace's Investor website. These conferences provide opportunities for NeuroPace to engage with investors and showcase its innovations in epilepsy treatment.
NeuroPace (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has announced its participation in two major healthcare conferences this September. The company will:
- Attend the Wells Fargo 2024 Healthcare Conference on September 4 in Boston, hosting one-on-one investor meetings
- Present at the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6 in New York
At the Morgan Stanley conference, CEO Joel Becker and CFO Rebecca Kuhn will participate in a fireside chat on September 6 at 8:30am ET, which will be webcast live. They will also host one-on-one investor meetings. A replay of the fireside chat will be available on NeuroPace's Investor website.
NeuroPace (NPCE) reported strong Q2 2024 financial results, with revenue growing 17% to $19.3 million compared to Q2 2023. The company increased its full-year 2024 revenue guidance to $76-$78 million. Key highlights include:
- Expanded gross margin to 73.4% from 72.5% in Q2 2023
- Decreased cash burn to $4.0 million from $4.4 million in Q2 2023
- Completed initial hiring of expanded commercial organization
- Continued progress in executing growth strategy, including expanding commercial organization and increasing active prescribing epileptologists
NeuroPace remains focused on generating broader adoption of RNS therapy and closing the treatment gap for drug-resistant epilepsy patients.
FAQ
What is the current stock price of Neuropace (NPCE)?
What is the market cap of Neuropace (NPCE)?
What is NeuroPace, Inc. known for?
What medical condition does the RNS® System primarily target?
Where is NeuroPace, Inc. based?
How does the RNS® System work?
Who are the primary customers for the RNS® System?
What recent achievements has NeuroPace made?
How does NeuroPace generate revenue?
Can the RNS® System treat conditions other than epilepsy?
What makes the RNS® System unique?
Who can be contacted for investor-related inquiries at NeuroPace?
